Elicio Therapeutics
Price & Volume
Stats
See moreOpen | $8.60 |
Previous Close | $8.72 |
Day Range | $8.52-$8.68 |
52W Range | $4.60-$12.62 |
Market Cap | $148.8M |
Shares Short | 749,923 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$3.98 |
News
See moreYahoo Finance • 5 days ago
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Yahoo Finance • 6 days ago
KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight
Yahoo Finance • 2 months ago
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
Yahoo Finance • 2 months ago
Elicio Therapeutics Reports Inducement Grants
About
CEO | Mr. Robert T. Connelly |
Address | 451 D Street, Boston, MA, United States, 02210 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 32 |
